Debevoise Advises Tarsadia Investments in Connection with the Reorganization of Amneal Pharmaceuticals

8 November 2023

Debevoise & Plimpton LLP is advising Tarsadia Investments in connection with the reorganization of Amneal Pharmaceuticals, Inc. (NYSE: AMRX), which includes eliminating its umbrella partnership-C-corporation structure. For more information, please see the company’s press release.

Tarsadia Investments is a multibillion-dollar private family office whose family members make high-conviction investments in category-defining companies globally, such as Amneal. Amneal Pharmaceuticals is a fully integrated global pharmaceuticals company with a diverse portfolio of approximately 270 pharmaceutical products, primarily within the United States.

The Debevoise team is led by M&A partner Andrew Bab and commercial litigation partner Shannon Rose Selden and includes M&A associate Katrina Mari Kaczynski, tax partner Stephen Jordan and associate Robert Nelson-Sullivan, and commercial litigation partner Zachary Saltzman and associate Matthew Sorensen.